We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Brian D. Nicholson
Brian D. Nicholson
Products
PRODUCTS
Fresenius Kabi USA, LLC
Nicholas P. Diorio
,
Brian D. Nicholson
,
Joseph Piechocki
, and
Nibin Varghese
Price:
$117.00
View
Antares Pharma, Inc.
Brian D. Nicholson
Price:
$117.00
View
BMC 1092, Inc. dba SOLO Laboratories, Inc.
Brian D. Nicholson
and
Vaishali J. Patel
Price:
$117.00
View
Sunstar Americas, Inc.
Stephen D. Eich
and
Brian D. Nicholson
Price:
$117.00
View
Fresenius Kabi USA, LLC
Michele L. Glendenning
and
Brian D. Nicholson
Price:
$117.00
View
Thornton Industries, Inc.
Brian D. Nicholson
Price:
$117.00
View
Grain Processing Corp.
Brian D. Nicholson
and
Peng Zhou
Price:
$117.00
View
Orsini Pharmaceutical Services, Inc.
Brian D. Nicholson
Price:
$117.00
View
NorthStar Medical Radioisotopes, LLC
Brian D. Nicholson
Price:
$117.00
View
Camphor and Allied Products, Ltd.
Brian D. Nicholson
Price:
$117.00
View
View All Products by Brian D. Nicholson
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
